Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 1, 2007, Pages 170-174

  Lalezari, Jacob P ^a   Ward, Douglas J ^b   Tomkins, Susan A ^c   Garges, Harmony P ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Dupont Circle Physicians Group   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Acquired immune deficiency syndrome; AIDS; Antiretroviral therapy; HIV 1 infection

Indexed keywords

BRECANAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ABNORMAL DREAMING; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DESCRIPTIVE RESEARCH; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC DISCOMFORT; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; IC 50; IN VITRO STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VIRUS INHIBITION; VIRUS RESISTANCE; VOMITING;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BENZODIOXOLES; CARBAMATES; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 34447581065     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm122     Document Type: Article

References (10)

1. Crum NF, Riffenburgh RH, Wegner S et al. Comparisons of causes of death and mortality rates among HIV-infected persons. Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194-200.
2. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362: 22-9.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. 10 October 2006; 1-113. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
4. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-65.
5. Hazen R, StClair M, Hanlon M et al. GW0385, a broad-spectrum, ultrapotent inhibitor of wild-type and protease-inhibitor-resistant HIV-1. In: Abstracts of the Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, 2003. Abstract 541. Antiviral Ther 2003; 8 Suppl 1: S329.
6. Miller JF, Andrews CW, Brieger M et al. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385. Bioorg Med Chem Lett 2006; 16: 1788-94.
7. Ford SL, Reddy YS, Anderson MT et al. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency vinis protease inhibitor. Antimicrob Agents Chemother 2006; 50: 2201-6.
8. Division of AIDS, NIAID. Division of AIDS Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases, 1992.
9. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13 125-31.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.